Poisoning Deaths Involving Opioid Analgesics — New York State, 2003–2012
Poisoning Deaths Involving Opioid Analgesics — New York State, 2003–2012
复制标题
涉及阿片类镇痛药的中毒死亡人数——纽约州，2003-2012 年
DOI：
--
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
T. A. Melnik
中科院分区：
文献类型：
--
作者：
M. Sharp;T. A. Melnik
在美国，涉及阿片类镇痛剂的死亡人数急剧增加。1999年记录的这类死亡人数约为4 000人，2013年增至16 235人，死亡率几乎翻了两番，从每100 000人中有1.4人死亡至5.1人。为了调查纽约州的这一增长，研究了2003至2012年间涉及阿片类镇痛剂的中毒死亡的趋势。使用的数据来源是纽约州生命统计多死因数据，包括来自纽约市(NYC)*和非纽约市报告司法管辖区的数据，以及全州医疗补助登记数据。与阿片类镇痛剂有关的死亡人数和占所有药物中毒死亡人数的百分比都有所增加，男性、白人、45-年龄段的人、居住在纽约市以外的人以及参加医疗补助的人的死亡率最高。分析发现，2012年，70.7%的阿片类止痛药死亡还涉及至少一种其他药物，最常见的是苯二氮卓类药物。这些结果突显出，通过纽约州追踪过度描述(I-STOP)法律的互联网系统(†)等举措，有可能缓解阿片类止痛剂相关死亡率上升的趋势。该法律于2013年8月27日生效。I-Stop下的条款包括要求提供者在为受控物质开具处方时咨询处方监测计划(PMP)登记处，以及他们使用电子处方。
Deaths involving opioid analgesics have increased dramatically in the United States. Approximately 4,000 such deaths were documented in 1999, increasing to 16,235 in 2013, reflecting a nearly quadrupled death rate from 1.4 to 5.1 deaths per 100,000. To investigate this increase in New York state, trends in poisoning deaths involving opioid analgesics from 2003 to 2012 were examined. Data sources used were New York state vital statistics multiple-cause-of-death data, consisting of data from both the New York City (NYC)* and non-NYC reporting jurisdictions, as well as statewide Medicaid enrollment data. Deaths involving opioid analgesics increased both in number and as a percentage of all drug poisoning deaths, and rates were highest among men, whites, persons aged 45-64 years, persons residing outside of NYC, and Medicaid enrollees. The analysis found that, in 2012, 70.7% of deaths involving opioid analgesics also involved at least one other drug, most frequently a benzodiazepine. These results underscore the potential to mitigate the trend of increasing opioid analgesic-related mortality through initiatives such as New York state's Internet System for Tracking Over-Prescribing (I-STOP) law,† which took effect on August 27, 2013. Provisions under I-STOP include the requirements that providers consult the Prescription Monitoring Program (PMP) Registry when writing prescriptions for controlled substances, and that they use electronic prescribing.